Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Change in Receivables (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Change in Receivables for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables changed N/A to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $28.2 million for FY2025, N/A changed from the prior year.
  • Change in Receivables for Q4 2025 was $2.7 million at Soleno Therapeutics, up from $882000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $2.7 million in Q4 2025, with the low at $882000.0 in Q3 2025.